About Celularity Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://celularity.com/
Frequently Asked Questions
What is the 52-week range for CELU?
The 52-week high is $2.55 and the 52-week low is $0.5601.
What is the P/E ratio for CELU?
The P/E ratio data is currently unavailable.
What is the dividend yield for CELU?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -272.44%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -345.45%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.20.
Analyst Recommendation Trends
Wall Street analyst consensus for CELU over the last few months:
Latest CELU News
Stock Market: Will S&P 500 Open Up or Down Today?
S&P 500 to open higher? Polymarket odds reach 70% as Wall Street digests September jobs, 24-year high Treasury yields, and Iran sanctions.
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
Fontaine Vitale represents a significant new market and revenue opportunity for Celularity in the Asia-Pacific regionFLORHAM PARK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today highlighted continued progress at Fontaine Vitale, a regenerative medicine and wellness center being developed in the Sanur Special Economic Zone
Celularity Q1 EPS $0.02 Up From $(0.84) YoY, Sales $3.846M Down From $11.426M YoY
Celularity (NASDAQ:CELU) reported quarterly earnings of $0.02 per share. This is a 102.38 percent increase over losses of $(0.84) per share from the same period last year. The company reported $3.846 million in sales
Celularity Announces Naveen Jain to Join Board of Directors
Viome founder and CEO brings a consumer-focused vision for bringing regenerative therapies to more people and advancing proactive healthFLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company, today announced that Naveen Jain, founder and Chief Executive Officer of Viome Life Sciences Inc. (“Viome”), will join its Board of Directors. Jain founded InfoSpace, Intelius, TalentWise and Moon Express and is
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
Plan combines up to $25 million in new capital with restructuring of $3 million in existing debt to support commercial execution and manufacturing expansion Company anticipates positive monthly operating cash flow by the end of Q1 2027 Philip A. Barach to join the Board, bringing financial expertise and a focus on capital discipline FLORHAM PARK, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company,
Celularity Announces Initial Closing Generating Over $10M In Gross Cash Proceeds From Private Placement Of Senior Secured Convertible Notes And Warrants
Plan combines up to $25 million in new capital with restructuring of $3 million in existing debt to support commercial execution and manufacturing expansionCompany anticipates positive monthly operating cash flow by the
Celularity Says It Regained Compliance With Nasdaq Minimum Bid Price And Market Value Of Listed Securities Rules; Delinquent Periodic Filing Deficiency Remains Outstanding
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001752828/000149315226042495/form8-k.htm
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-23 | Philip & Daniele Barach Family Trust | +1,457,765 | - | - |
| 2026-09-23 | Philip & Daniele Barach Family Trust | +1,457,765 | - | - |
| 2026-09-23 | Philip & Daniele Barach Family Trust | +1,177,000 | - | - |
| 2026-09-23 | Philip & Daniele Barach Family Trust | +2,140,000 | - | - |
| 2026-09-23 | Philip & Daniele Barach Family Trust | +192,771 | - | - |
| 2026-09-23 | Barach Daniele Wolf | +1,457,765 | - | - |
| 2026-09-23 | Barach Daniele Wolf | +1,457,765 | - | - |
| 2026-09-23 | Barach Daniele Wolf | +1,177,000 | - | - |
| 2026-09-23 | Barach Daniele Wolf | +2,140,000 | - | - |
| 2026-09-23 | Barach Daniele Wolf | +192,771 | - | - |
| 2026-09-23 | Barach Philip Alan | +1,457,765 | - | - |
| 2026-09-23 | Barach Philip Alan | +1,457,765 | - | - |
| 2026-09-23 | Barach Philip Alan | +1,177,000 | - | - |
| 2026-09-23 | Barach Philip Alan | +2,140,000 | - | - |
| 2026-09-23 | Barach Philip Alan | +192,771 | - | - |
| 2026-06-19 | Philip & Daniele Barach Family Trust | -839,160 | - | - |
| 2026-06-19 | Philip & Daniele Barach Family Trust | -1,204,819 | - | - |
| 2026-06-19 | Barach Philip Alan | -839,160 | - | - |
| 2026-06-19 | Barach Philip Alan | -1,204,819 | - | - |
| 2026-06-19 | Barach Daniele Wolf | -839,160 | - | - |
| 2026-06-19 | Barach Daniele Wolf | -1,204,819 | - | - |
| 2026-04-13 | Brigido Stephen | -821 | - | - |
| 2026-04-13 | Brigido Stephen | -268 | $1.28 | $343 |
| 2026-04-13 | Brigido Stephen | +821 | - | - |
| 2026-04-13 | Haines John R | -1,641 | - | - |
| 2026-04-13 | Haines John R | -583 | $1.28 | $746 |
| 2026-04-13 | Haines John R | +1,641 | - | - |
| 2026-04-13 | Hariri Robert J | -3,281 | - | - |
| 2026-04-13 | Hariri Robert J | -1,182 | $1.28 | $1,513 |
| 2026-04-13 | Hariri Robert J | +3,281 | - | - |
| 2026-01-12 | Parks Diane L. | +30,000 | - | - |
| 2026-01-12 | Ling Geoffrey M.D. | +19,231 | - | - |
| 2026-01-12 | LeVien Vincent | +28,847 | - | - |
| 2026-01-12 | Diamandis Peter | +20,385 | - | - |
| 2026-01-12 | Ling Geoffrey M.D. | +19,231 | - | - |
| 2026-01-12 | LeVien Vincent | +28,847 | - | - |
| 2026-01-12 | Parks Diane L. | +30,000 | - | - |
| 2026-01-12 | Diamandis Peter | +20,385 | - | - |
| 2025-12-29 | LeVien Vincent | +156,250 | - | - |
| 2025-12-29 | LeVien Vincent | +125,000 | - | - |
| 2025-12-29 | Ling Geoffrey M.D. | +156,250 | - | - |
| 2025-12-29 | Ling Geoffrey M.D. | +125,000 | - | - |
| 2025-12-29 | Parks Diane L. | +156,250 | - | - |
| 2025-12-29 | Parks Diane L. | +125,000 | - | - |
| 2025-12-29 | Diamandis Peter | +156,250 | - | - |
| 2025-12-29 | Diamandis Peter | +125,000 | - | - |
| 2025-12-19 | Parks Diane L. | +67,416 | - | - |
| 2025-12-19 | Ling Geoffrey M.D. | +67,416 | - | - |
| 2025-12-19 | Diamandis Peter | +67,416 | - | - |
| 2025-11-19 | Diamandis Peter | +47,042 | - | - |
| 2025-11-19 | Parks Diane L. | +61,539 | - | - |
| 2025-11-19 | LeVien Vincent | +3,699 | - | - |
| 2025-11-19 | Ling Geoffrey M.D. | +44,379 | - | - |